Parkinson disease
MONDO:0005180A progressive degenerative disorder of the central nervous system characterized by loss of dopamine producing neurons in the substantia nigra and the presence of Lewy bodies in the substantia nigra and locus coeruleus. Signs and symptoms include tremor which is most pronounced during rest, muscle rigidity, slowing of the voluntary movements, a tendency to fall back, and a mask-like facial expression.
Also known as: PD, Parkinson disease, Parkinson's disease, paralysis agitans
1114 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental Parkinson's drug talineuren put to early safety test
Disease control TerminatedThis early-stage trial tested the safety of an intravenous drug called talineuren (liposomal GM1) in 22 people with Parkinson's disease. The study was open-label and designed to find a safe dose, but it was terminated before completion. No conclusions about effectiveness can be d…
Phase: PHASE1 • Sponsor: InnoMedica Schweiz AG • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Parkinson's drug trial halted: what we learned from UCB0599
Disease control TerminatedThis study looked at whether taking UCB0599 early or later could slow brain changes in people with Parkinson's disease. It involved 428 adults who had already completed an earlier study. The trial was stopped early, but researchers measured brain scans and medication use over 18 …
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Immunotherapy plus radiation for early lung cancer: trial halted early
Disease control TerminatedThis phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise, high-dose radiation (SBRT) could help prevent early-stage non-small cell lung cancer from returning. The study enrolled 448 people with stage I or II lung cancer who could not hav…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Parkinson's drug trial halted early: what happened?
Disease control TerminatedThis study tested an experimental drug called VENT-02 in 29 people with mild to moderate Parkinson's disease. The drug aims to reduce brain inflammation by blocking a protein called NLRP3. The trial was terminated early, so we don't have clear results on whether it helps symptoms…
Phase: PHASE1, PHASE2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer cocktails show promise, but study halted early
Disease control TerminatedThis early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was termina…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Neck-Worn swallow detector fails key test
Diagnosis TerminatedThis study tested a wearable device that sits on the neck to detect swallowing problems in people with conditions like stroke, Parkinson's, multiple sclerosis, Alzheimer's, or dementia. The device was compared to a standard X-ray test. Unfortunately, the device did not meet the a…
Phase: NA • Sponsor: Société des Produits Nestlé (SPN) • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Parkinson's drug side effect targeted by antioxidant NAC – but trial stalls
Symptom relief TerminatedThis study tested whether N-acetylcysteine (NAC), an antioxidant, could help reduce impulse control disorders caused by Parkinson's medications. Only 14 people with mild-to-moderate symptoms were enrolled before the trial was stopped early. The goal was to see if 10 weeks of NAC …
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Robot trainer aims to help Parkinson's patients walk better
Symptom relief TerminatedThis study tested a robotic device called the G-EO Gait Trainer to help people with Parkinson's disease improve their walking. The device supports the body and guides leg movements to make walking practice safer and more effective. The trial was terminated early, so only limited …
Phase: NA • Sponsor: Indiana University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Walking poles tested for Parkinson's: a simple step forward?
Symptom relief TerminatedThis study looked at whether using walking poles during an 8-week independent walking program could improve walking and activity levels in people with Parkinson's disease. Eleven participants were assigned to walk with or without poles at least three times a week. The trial was t…
Phase: NA • Sponsor: Pacific Northwest University of Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Parkinson's sleep study halted early – what we know
Symptom relief TerminatedThis study looked at whether the drug safinamide (Xadago) could improve sleep quality in people with Parkinson's disease. Eleven participants took safinamide for 12 weeks while their sleep was measured. The trial was terminated early, so the results are not conclusive.
Phase: PHASE4 • Sponsor: Alain Kaelin • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Parkinson's apathy drug trial stalls after just 8 patients
Symptom relief TerminatedThis study tested whether istradefylline, a drug already approved for motor symptoms in Parkinson's, could also improve apathy and motivation. Only 8 people enrolled before the trial was terminated early. The results are too limited to draw any conclusions.
Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Can zapping two brain areas at once stop Parkinson's freezing?
Symptom relief TerminatedThis study tested whether a high-dose magnetic stimulation (TMS) targeting both motor and cognitive brain areas could better reduce freezing of gait in people with Parkinson's disease compared to standard low-dose stimulation of just the motor area. The trial planned to enroll 64…
Phase: NA • Sponsor: Anhui Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Parkinson's inhaler trial halted after just 8 patients
Symptom relief TerminatedThis study tested an inhaled form of apomorphine (AZ-009) to quickly treat 'OFF' episodes in people with Parkinson's disease—times when symptoms like stiffness or trouble moving return between regular medication doses. The trial was planned for more participants but was terminate…
Phase: PHASE2 • Sponsor: Alexza Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Scientists probe Brain's consciousness switch during anesthesia
Knowledge-focused TerminatedThis study looked at how anesthesia changes brain activity in people with Parkinson's disease or essential tremor who were already scheduled for deep brain stimulation (DBS) surgery. Researchers recorded brain signals during a short period of anesthesia to understand which circui…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Brain wave test could spot stubborn depression
Knowledge-focused TerminatedThis study aimed to find brain and movement markers in people with a type of depression that doesn't respond to standard antidepressants, called anhedonic depression. Researchers measured brain waves (P300), walking speed, and hand movements in 36 participants. The goal was to id…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Treadmill training may slow Parkinson's by fighting inflammation
Knowledge-focused TerminatedThis study looked at whether intensive treadmill exercise can improve motor symptoms and reduce inflammation in people with early-stage Parkinson's disease. Researchers measured changes in movement scores and blood markers of nerve damage and inflammation in 30 patients who eithe…
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:10 UTC